Trial Profile
A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 06 Mar 2023
Price :
$35
*
At a glance
- Drugs Emirodatamab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; First in man
- Sponsors Amgen
- 28 Feb 2023 Status changed from recruiting to discontinued.
- 21 Nov 2022 Planned End Date changed from 5 May 2027 to 13 May 2025.
- 21 Nov 2022 Planned primary completion date changed from 5 May 2027 to 13 May 2025.